"alpha-Fetoproteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
    
			
			
				
				
					
						| Descriptor ID | 
										
							D000509
						 | 			
					
					
						| MeSH Number(s) | 
						
							 D12.776.124.790.106.092 D12.776.320.525.500 D12.776.377.228.500 D12.776.377.715.085.092 D23.101.140.050 
						 | 
					
					
						| Concept/Terms | 
						
							
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "alpha-Fetoproteins".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "alpha-Fetoproteins".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "alpha-Fetoproteins" by people in this website by year, and whether "alpha-Fetoproteins" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2000 | 1 | 0 | 1 | 
| 2009 | 1 | 0 | 1 | 
| 2015 | 0 | 2 | 2 | 
| 2017 | 0 | 1 | 1 | 
| 2018 | 0 | 1 | 1 | 
| 2020 | 0 | 2 | 2 | 
| 2023 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "alpha-Fetoproteins" by people in Profiles.
						
					
								- 
								
Impact of tumor markers on diagnosis, treatment and prognosis in CNS germ cell tumors: correlations with clinical practice and histopathology. Brain Tumor Pathol. 2023 Apr; 40(2):124-132.
															
								 
							
								- 
								
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open. 2020 08; 5(4).
															
								 
							
								- 
								
Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical ß-catenin-dependent mechanism. Sci Rep. 2020 06 29; 10(1):10578.
															
								 
							
								- 
								
Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):296-301.
															
								 
							
								- 
								
Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol. 2017 Aug; 93:100-106.
															
								 
							
								- 
								
10-Year Analysis of Benign Ovarian Teratomas: Outcomes and Follow-Up. Am Surg. 2017 Mar 01; 83(3):e90-92.
															
								 
							
								- 
								
Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016 Jan; 36(1):108-18.
															
								 
							
								- 
								
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 May; 21(5):599-606.
															
								 
							
								- 
								
Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice. Carcinogenesis. 2015 Apr; 36(4):429-40.
															
								 
							
								- 
								
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012 May; 56(5):1112-1120.